[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypogammaglobulinemia-acquired\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypogammaglobulinemia-acquired":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":44},"100591134","phase-2-study-of-igpro20-to-prevent-infection-in-people-with-multiple-myeloma-and-hypogammaglobulinemia-100591134",false,"NCT06976476","Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia","Prospective Randomized Phase II Study Evaluating Efficacy and Safety of IgPro20 as Infection Prophylaxis in Patients With Multiple Myeloma and Hypogammaglobulinemia Receiving Therapy With a Bispecific Monoclonal Antibody (BsAbs)","Inclusion Criteria:\n\n* Diagnosis of RRMM receiving a commercially available bispecific antibody\n* Received at least 1 but no more than 4 cycles of BsAb\n* Males or females greater than or equal to 18 years old at the time of consent\n* ECOG ≤ 3\n* Life expectancy \\> 12 months\n\nExclusion Criteria:\n\n* HSCT within 3 months before enrollment\n* Planned CAR-T therapy in the next 6 months\n* \\>1 major (deep-seated) infection within the preceding 3 months\n* HIV infection, Active HCV, or Active HBV infection\n* Pregnancy\n* Neutrophils \\\u003C 500 x 10\\^9 per mL, Platelets \\\u003C 30 x 10\\^9 per mL\n* History of cancer other than MM in the last 3 years requiring active chemotherapy or radiation\n* Known reaction\u002Fallergy to IgG products\n* Intracranial hemorrhage or embolic CVA in the last 6 months\n* Hyperproteinemia\n* Protein-losing enteropathy\n* Creatinine Cl \\\u003C30 ml\u002Fmin\n* Documented progression on BsAb\n* Known history of Hyperprolinemia\n* On current or previous IVIG (in the last 3 months)","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).",[26,27,28],"Multiple Myeloma","Hypogammaglobulinemia","Hypogammaglobulinemia, Acquired",[26,27,30,31,32],"IgPro20","Memorial Sloan Kettering Cancer Center","24-137","RECRUITING","2026-03-10",{"date":36,"type":37},"2026-03-11","ACTUAL",{"date":39,"type":37},"2025-05-08",{"date":41,"type":20},"2029-05-08",{"name":31,"class":43},"OTHER",8,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100592139","immunoglobulin-for-hypogammaglobulinemia-due-to-chimeric-antigen-receptor-t-cell-therapy-100592139","NCT06989541","Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy","ICART","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Severe HGG defined as total IgG \\\u003C4 g\u002FL (after subtracting the IgG paraprotein fraction, if present)\n3. Treated with CD19 targeted CAR T cell therapy in the past 6 months\n4. Consent to receive plasma-derived productions\n5. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. Inability to comply with study procedures\n2. Pregnancy or planning to conceive\n3. Breastfeeding\n4. Protein-losing conditions that may contribute to HGG (e.g., protein-losing enteropathy, nephrotic syndrome)\n5. SCIG infusion in the prior 3 months.\n6. History of allergy or severe reactions to immune globulin productions",{"count":53,"type":20},30,"OBSERVATIONAL","Chimeric antigen receptor (CAR) T cells are special immune cells taken from a patient and changed in a lab to help them find and attack cancer cells. These cells are designed to look for a marker called CD19, which is found on both cancer cells and healthy B cells (a type of white blood cell). Because of this, CAR T cells can also destroy healthy B cells. This can lead to a strong drop in B cells and cause a condition called hypogammaglobulinemia (HGG), which makes it harder for the body to fight infections. Serious infections are common in people treated with CAR T cells and are a major reason for death that is not caused by the return of cancer.\n\nTo help prevent infections, patients with HGG often get immunoglobulin replacement therapy (IRT), which gives them the antibodies they need. This treatment can be given through a vein (IVIG) or under the skin (SCIG). The goal of this project is to study how often these patients get bacterial infections, how they feel about their quality of life and treatment, and what side effects they may have when treated with IVIG or SCIG after CAR T-cell therapy.",[28],[58,59,60],"secondary immunodeficiency","CAR T","immune globulin","2025-07-02",{"date":63,"type":37},"2025-07-03",{"date":65,"type":37},"2025-06-01",{"date":67,"type":20},"2027-05-01",{"name":69,"class":43},"University of Alberta",1]